We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?

Expert Review of Neurotherapeutics

Volumn 14, Issue 2, 2014, Pages 127-130

  Fragoso, Yara D ^a   Arruda, Niedja M ^b   Arruda, Walter O ^c   Brooks, Joseph B B ^a   Correa, Eber C ^d   Damasceno, Alfredo ^e   Damasceno, Carlos A ^f   Ferreira, Maria L B ^b   Giacomo, Maria C B ^g   Gomes, Sidney ^h   Gonçalves, Marcus V M ⁱ   Grzesiuk, Anderson K ^j   Kaimen Maciel, Damacio R ^k   Lopes, Josiane ^k   Machado, Suzana C N ^l   Oliveira, Celso L S ^a   Stella, Carla R A V ^m  

^a UNIVERSIDADE METROPOLITANA DE SANTOS   (Brazil)

^b HOSPITAL DA RESTAURAÇÃO   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d MS Unit   (Brazil)

^e UNIVERSITY OF CAMPINAS   (Brazil)

^f FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^g MS Unit   (Brazil)

^h HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

ⁱ Centro Hospitalar Unimed   (Brazil)

^j Rehabilitation Center Dom Aquino Correa   (Brazil)

^k STATE UNIVERSITY OF LONDRINA   (Brazil)

^l HOSPITAL GOVERNADOR CELSO RAMOS   (Brazil)

^m Neurology   (Brazil)

more..

Author keywords

fingolimod; JC virus; multiple sclerosis; natalizumab; relapses

Indexed keywords

BETA INTERFERON; CORTICOSTEROID; FINGOLIMOD; GLATIRAMER; NATALIZUMAB;

ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HERPES ZOSTER; HUMAN; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84893060675     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.874947     Document Type: Article

References (27)

1. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest 2012;122:1180-8
2. McCoyd M. Update on therapeutic options for multiple sclerosis. Neurol Clin 2013;31: 827-45
3. McCormack PL. Natalizumab: A review of its use in the management of relapsing-remitting multiple sclerosis. Drugs 2013;73(13):1463-81
4. Fernández O. Best practice in the use of natalizumab in multiple sclerosis. Ther Adv Neurol Disord 2013;6:69-79
5. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143-52
6. Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011;10:CD007621
7. Fragoso YD, Alves-Leon SV, Arruda WO, et al. Natalizumab adverse events are rare in patients with multiple sclerosis. Arq Neuropsiquiatr 2013;71:137-41
8. Damasceno A, von Glehn F, Martinez AR, et al. Early onset of natalizumab-related progressive multifocal leukoencephalopathy. Mult Scler 2011;17:1397-8
9. Baumgartner A, Stich O, Rauer S. Clinical and radiological disease reactivation after cessation of long-Term therapy with natalizumab. Int J Neurosci 2012;122:35-9
10. Rigau V, Mania A, Béfort P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 2012;79:2214-16
11. Marousi S, Travasarou M, Karageorgiou CE, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012;79:2160
12. Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010;68:409-11
13. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186-91
14. Borriello G, Prosperini L, Marinelli F, et al. Observations during an elective interruption of natalizumab treatment: A post-marketing study. Mult Scler 2011;17:372-5
15. Papeix C, Depaz R, Tourbah A, et al. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse. Mult Scler 2011;17:1520-2
16. Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: A post-marketing study. Eur J Neurol 2012;19:783-7
17. Magraner MJ, Coret F, Navarré A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: A prospective, 6-month observational study. J Neurol 2011;258:1805-11
18. Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol 2013;20:87-94
19. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: Recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011;258:1665-9
20. Gobbi C, Meier DS, Cotton F, et al. Interferon beta 1b following natalizumab discontinuation: One year, randomized, prospective, pilot trial. BMC Neurol 2013;13:101
21. Cree B, De Seze J, Fox R, et al. RESTORE Study: Effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity 2012; (P06.168). Neurology 2012; 78(Meeting Abstracts 1):P06.168
22. Comi G, Gold R, Dahlke F, et al. Overall safety and relapse outcomes in fingolimod-Treated patients previously treated with natalizumab in the 4-month, open-label FIRST study [Poster 537]. 23rd European Neurology Society (ENS) Meeting, Barcelona, Spain; 2013
23. Havla J, Tackenberg B, Hellwig K, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol 2013;260: 1382-7
24. Daelman L, Maitrot A, Maarouf A, et al. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler 2012;11:1647-9
25. Sempere AP, Martín-Medina P, Berenguer-Ruiz L, et al. Switching from natalizumab to fingolimod: An observational study. Acta Neurol Scand 2013;128:e6-e10
26. Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012;79:2004-5
27. Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012;18:1650-2